political trust

A nine-member political body, tasked with filling the leadership vacuum in Haiti, has been created although their names have not been made public. Also: the US says Iran could attack Israel with drones and missiles within hours, and a Norwegian minister resigns over plagiarism claims.

Hosted on Acast. See acast.com/privacy for more information.

A week that was dedicated to show that the Conservatives have a plan on how to 'stop the boats' has instead been dominated by tragedy - the death of 41 migrants in the sea near Lampedusa while the deputy chair of the Tory party told Channel-crossing migrants to 'f*** off' back to France - and farce - as 39 asylum seekers were removed off barge accommodation just days after moving in due to a bacterial infection in the nearby waters.

Has this week been a major step back for Rishi Sunak in his attempts to fulfil one of his flagship policies? We discuss with Sir Craig Oliver, former director of communications at No.10.

We talk parliamentary standards with Sir Chris Bryant - and Gary Lineker joins us to justify to heartbroken Spurs fan Jon why Harry Kane is right to leave Tottenham for Bayern Munich.

Editor: Tom Hughes

Senior Producer: Gabriel Radus

Producer: Laura FitzPatrick

Social Media Editor: Georgia Foxwell

Planning Producer: Alex Barnett

Video Producer: Rory Symon

The News Agents is a Global Player Original and a Persephonica Production.

David Aaronovitch has left The Times after nearly 18 years at the paper, and after three years on Stories of Our Times.

As well as presenting this podcast, every week David discussed the news with friend and fellow columnist Danny Finkelstein on Matt Chorley's Times Radio show. On Tuesday, Matt and Danny said goodbye to David with an hour-long special in which they discuss the Brexit deal, trust in politicians, and listener questions for the 'Cerberus of Columnists'.

This podcast was brought to you thanks to the support of readers of The Times and The Sunday Times. Subscribe today: thetimes.co.uk/storiesofourtimes.

Hosted on Acast. See acast.com/privacy for more information.

Click here to join the member exclusive portion of my show: https://utm.io/ueSEl

The foreman of a Georgia grand jury opens her mouth and likely sinks the “insurrection” case against Trump, the Donald visits East Palestine and buys water and McDonalds for the locals, and a new study shows that COVID vaccine mandates did nothing to stop cases and deaths from the virus.

- - - 

DailyWire+:

Become a DailyWire+ member for 40% off to access movies, shows, documentaries, and more: https://bit.ly/3jJQBQ7 

Shop the Jeremy’s Razors Presidents’ Day sale and get 30% off any razor: https://bit.ly/3xuFD43 

Get your Michael Knowles merch here: https://bit.ly/3X6tlKY 

 - - - 

Today’s Sponsors:

Cynch - Download the Cynch app and get your first tank exchange for just $10 with promo code KNOWLES. Visit http://cynch.com/offer for details.

Epic Will - Use Promo Code 'KNOWLES' for 10% off your Will: https://www.epicwill.com/

- - -

Socials:

Follow on Twitter: https://bit.ly/3RwKpq6 

Follow on Instagram: https://bit.ly/3BqZLXA 

Follow on Facebook: https://bit.ly/3eEmwyg 

Subscribe on YouTube: https://bit.ly/3L273Ek 

Learn more about your ad choices. Visit podcastchoices.com/adchoices

Hosted on Acast. See acast.com/privacy for more information.

GOP candidate J.R. Majewski appears to lie about his military service, Christiane Amanpour discusses her interview with Iran's president, and Tyler Perry talks about "A Jazzman's Blues."

See omnystudio.com/listener for privacy information.

Public health officials and private researchers have vowed to develop a coronavirus vaccine in record time. But could that rush backfire? Guest: Jan Hoffman, a health reporter for The New York Times. For more information on today’s episode, visit nytimes.com/thedaily

Background reading:

• Billions of dollars are being poured into developing a coronavirus vaccine, but the rapid timetable may be creating even more vaccine-hesitant patients.
• Three vaccine developers report that early trials showed promising results with minimal side effects, but one researcher cautioned, “There is still a long way to go.”